Delix Therapeutics

Delix Therapeutics, Inc. ("Delix")
TypePrivate
Industry
Founded2019
HeadquartersBoston, Massachusetts
Key peopleMark Rus (Chief Executive Officer)
Websitedelixtherapeutics.com

Delix Therapeutics is an American biotech company based in Boston, Massachusetts.[1][2] The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD).[3][2] It was co-founded in 2019 by David E. Olson and Nick Haft.[4][2]

Company History

The company was founded to develop novel, non-hallucinogenic psychoplastogens, also known as neuroplastogens, to better treat mental health disorders at scale.[2] Nick Haft and David E. Olson founded the company following Olson's discovery that psychedelics are highly potent neuroplasticity-promoting compounds.[3][2] In September 2021, Delix secured a Series A financing round, the largest in the space, to continue their work focused on neuroplastogens and neuroplasticity therapeutics.[5] Also in Fall of 2021, Delix joined the National Institute on Drug Abuse industry partnering program to screen psychoplastogens in models of substance use disorder.[3] In 2021, the company expanded the leadership team, adding a new CEO,[6] CSO,[1] and CMO[1]

Awards

In 2021, Delix was named one of the Fierce 15 of Biotech.[7] In 2022, Nature named Delix Spinout of the Year[8] and Delix was awarded the Healthcare Businesswomen's Association (HBA) ACE award.[9] In 2023, Delix was a finalist for the Prix Galien award for Best Startup[10] and the BWB award for Biotech Innovation of the Year[11] and won the Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year.[12]

Product Candidates

To date, the company has synthesized over 2,000 novel psychoplastogens.[13] Many of these small molecule compounds are analogs of known psychedelics such as ibogaine and 5-MeO-DMT.[14] Delix focuses on the development of non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.[15] Their compounds have been engineered to lack cardiotoxicity and psychostimulant properties characteristic of other first-generation psychoplastogens.[16] The company's known drug candidates include zalsupindole (DLX-001; AAZ-A-154), tabernanthalog (DLX-007), JRT,[17] and DLX-159.[18][19] Delix has licensed these compounds from UC Davis.[20]

See also

References

  1. 1 2 3 LaHucik, Kyle (2021-09-27). "Delix raises $70M to test psychedelic analogs for treating brain disorders in clinical trials next year". Fierce Biotech. Retrieved 2022-06-08.
  2. 1 2 3 4 5 Dalton, Clayton (13 March 2026). "Why Do Mind-Altering Drugs Make People Feel Better?". The New Yorker. Retrieved 21 March 2026.
  3. 1 2 3 Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip". Forbes. Retrieved 2022-05-18.
  4. ↑ Kathan, Jesse (December 13, 2021). "Harnessing Psychedelics for Healing". Comstock's magazine. Retrieved 2022-06-08.
  5. ↑ Salarizadeh, Cynthia (2022-03-11). "How Capital Markets Are Fueling Psychedelic Medicine Growth". Rolling Stone. Retrieved 2022-06-08.
  6. ↑ "Shire neuro head lands at Delix Therapeutics as CEO". FierceBiotech. 18 March 2021. Retrieved 2021-08-27.
  7. ↑ https://www.fiercebiotech.com/special-report/fierce-biotech-s-2021-fierce-15-0
  8. ↑ Garber, Ken (19 August 2022). "Delix Therapeutics: psychedelics without the trip". Nature Biotechnology. doi:10.1038/d41587-022-00006-0. PMID 35986098. S2CID 251694020.
  9. ↑ "Delix Therapeutics and Pfizer UK Recognized as Gender Equity Champions for Women in the Workplace by Healthcare Businesswomen's Association" (Press release).
  10. ↑ "The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"" (Press release).
  11. ↑ "Award Categories".
  12. ↑ "2023 Winners".
  13. ↑ Yakowicz, Will. "U.S. Government Will Test Ibogaine Derivative As An Addiction Treatment". Forbes. Retrieved 2022-06-08.
  14. ↑ Andy Extance2020-12-17T14:30:00+00:00. "Chemists tame shamanic addiction treatment". Chemistry World. Retrieved 2022-06-08.{{cite web}}: CS1 maint: numeric names: authors list (link)
  15. ↑ "A new psychedelics player emerges to treat mental health disorders — minus the hallucinogenic effects". Endpoints News. Retrieved 2022-06-07.
  16. ↑ scientificinquirer (2022-03-14). "Industry Matters: Delix Therapeutics is taking Next-Gen psychedelics out of the lab and into the clinic". Scientific Inquirer. Retrieved 2022-06-07.
  17. ↑ Tuck, Jeremy R.; Dunlap, Lee E.; Khatib, Yara A.; Hatzipantelis, Cassandra J.; Weiser Novak, Sammy; Rahn, Rachel M.; Davis, Alexis R.; Mosswood, Adam; Vernier, Anna M. M.; Fenton, Ethan M.; Aarrestad, Isak K.; Tombari, Robert J.; Carter, Samuel J.; Deane, Zachary; Wang, Yuning (2025-04-22). "Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential". Proceedings of the National Academy of Sciences of the United States of America. 122 (16) e2416106122. doi:10.1073/pnas.2416106122. ISSN 1091-6490. PMC 12037037. PMID 40228113.
  18. ↑ Brown, Grace (6 March 2021). "Can we take the high out of psychedelics?". Wired UK.
  19. ↑ Rasmussen K, Agrawal R, Felts A, Leach P, Gillie D, Mungenast A, McTighe S, Chytil M, Meyer R, Rus M, Koenig A, Olson D, Salinas E (2024). "ACNP 63rd Annual Meeting: Poster Abstracts P1-P304: P252. DLX-159: A Novel, Next Generation, Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases" (PDF). Neuropsychopharmacology. 49 (S1): 65–235 (207–207). doi:10.1038/s41386-024-02011-0. ISSN 0893-133X. PMC 11627186. PMID 39643633. Retrieved 31 January 2025.
  20. ↑ Peters, Jamie; Olson, David E (January 2021). "Engineering Safer Psychedelics for Treating Addiction". Neuroscience Insights. 16: 263310552110338. doi:10.1177/26331055211033847. PMC 8295933. PMID 34350400.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.